| Identification | Back Directory | [Name]
Pyrido[3,2-d]pyrimidine-2,4-diamine, N4-butyl-6-[[4-[(dimethylamino)methyl]phenyl]methyl]- | [CAS]
2230218-36-5 | [Synonyms]
Pyrido[3,2-d]pyrimidine-2,4-diamine, N4-butyl-6-[[4-[(dimethylamino)methyl]phenyl]methyl]- | [Molecular Formula]
C21H28N6 | [MOL File]
2230218-36-5.mol | [Molecular Weight]
364.49 |
| Chemical Properties | Back Directory | [Boiling point ]
557.5±60.0 °C(Predicted) | [density ]
1.174±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
8.75±0.28(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50=24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2[1]. | [References]
[1] He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64(21):15716-15726. DOI:10.1021/acs.jmedchem.1c00961 |
|
|